Roche's faricimab injected every 16 weeks proves non-inferior to aflibercept injected every eight weeks in patients with “wet” age-related macular degeneration
San Diego Academy of Regenerative Therapies publishes article about first-in-human clinical trial using adipose-derived SVF to treat post-COVID-19 patients suffering lung damage